Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 49.3% in July

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the target of a large drop in short interest in July. As of July 31st, there was short interest totaling 1,385 shares, a drop of 49.3% from the July 15th total of 2,733 shares. Based on an average daily trading volume, of 790 shares, the short-interest ratio is presently 1.8 days. Currently, 0.0% of the company’s stock are sold short.

Institutional Trading of Molecular Partners

An institutional investor recently raised its stake in Molecular Partners stock. SmartHarvest Portfolios LLC grew its stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) by 26.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,543 shares of the company’s stock after buying an additional 3,232 shares during the period. SmartHarvest Portfolios LLC’s holdings in Molecular Partners were worth $62,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 26.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research note on Wednesday, July 8th. HC Wainwright restated a “buy” rating on shares of Molecular Partners in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.38.

Molecular Partners Price Performance

Molecular Partners stock traded up $0.01 during midday trading on Tuesday, reaching $4.26. The company’s stock had a trading volume of 534 shares, compared to its average volume of 4,954. The stock has a market capitalization of $171.86 million, a P/E ratio of -2.19 and a beta of 1.08. The stock’s 50-day simple moving average is $3.99 and its 200-day simple moving average is $4.23. Molecular Partners has a 52-week low of $3.53 and a 52-week high of $5.36.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.